Patients diagnosed with non-Hodgkin lymphoma are told they’ll achieve remission with first-line chemotherapy. But about 50% of them don’t, as their cancer resists treatment after treatment. They are running out of options…and hope. They need a reason to believe complete remission can still exist after treatment failure. YESCARTA is the first CAR T-cell therapy approved for NHL. It can give 3rd-line patients something more than hope––it can give them a chance for complete remission. With a strategically choreographed ecosystem focused on messages of empowerment and hope, we are able to provide patients the resources they need to fight for their survival.

Our goal was to give patients not only hope, but a chance for real remission. Together, with patients and oncologists, we are all succeeding.

Art Direction

Brand Identity

Brand Strategy

UX + Visual Design